U.S. Stock News

CarMax, Inc. ( NYSE:KMX ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...

Key Insights Significantly high institutional ownership implies Aldeyra Therapeutics' stock price is sensitive to their...

Some THOR Industries, Inc. ( NYSE:THO ) shareholders may be a little concerned to see that the Senior VP & COO, W...

If you are wondering whether Revolution Medicines at around US$120 per share reflects its real worth, you are not alone. This article is designed to help you frame that question clearly. The stock closed at US$120.28 recently, with returns of 1.4% over 7 days, 52.7% over 30 days, 52.2% year to date, 198.5% over 1 year and 337.1% over 3 years, which naturally raises questions about how expectations and risk are being priced in. Recent news flow around Revolution Medicines has focused on its...

SunOpta Inc. ( NASDAQ:STKL ) shareholders are no doubt pleased to see that the share price has bounced 25% in the last...

It might be of some concern to shareholders to see the Atlanticus Holdings Corporation ( NASDAQ:ATLC ) share price down...

The Bank of New York Mellon Corporation ( NYSE:BK ) stock is about to trade ex-dividend in four days. The ex-dividend...

Balchem's (NASDAQ:BCPC) stock is up by a considerable 12% over the past three months. Since the market usually pay for...

Heritage Global Inc. ( NASDAQ:HGBL ) shareholders should be happy to see the share price up 15% in the last month. But...

Universal Electronics Inc. ( NASDAQ:UEIC ) shareholders are no doubt pleased to see that the share price has bounced...

Key Insights Significantly high institutional ownership implies Inseego's stock price is sensitive to their trading...

CG Oncology (CGON) is back in focus after accelerating the topline data timeline for its Phase 3 PIVOT-006 trial, the first randomized study for intermediate-risk non muscle invasive bladder cancer patients. See our latest analysis for CG Oncology. The accelerated PIVOT-006 timeline sits against a strong recent run, with a 30 day share price return of 40.23% and a 1 year total shareholder return of 88.20%, suggesting momentum has been building around the story. If CG Oncology’s progress has...

Earlier this week, UBS analyst Leonardo Olmos upgraded Millicom International Cellular (TIGO) to a buy rating, citing increased confidence in the company’s growth outlook as it expands telecom services across Latin America and pursues acquisitions in Ecuador and Uruguay. This shift in analyst sentiment highlights how Millicom’s regional expansion and service diversification are increasingly shaping market perceptions of its longer-term prospects. We’ll now examine how UBS’s renewed...

In recent days, Centessa Pharmaceuticals reported new preclinical data showing its selective OX2R agonist reduced behavioral despair and improved wakefulness in animal models of major depressive disorder, while also outlining plans to broaden its orexin pipeline across neuropsychiatric conditions with high unmet need. Coupled with strong analyst support, leadership changes, and a planned US$250,000,000 public offering to fund late-stage trials, these developments highlight how Centessa is...

Otter Tail (OTTR) just approved a higher quarterly dividend of $0.5775 per share, lifting the indicated annual payout to $2.31 and extending its dividend track record into an 88th consecutive year. See our latest analysis for Otter Tail. At a share price of $87.85, Otter Tail has logged a 6.98% 1 month share price return and 13.11% 3 month share price return, while its 5 year total shareholder return of 139.86% points to strong long term compounding alongside the newly higher dividend. If...

Recently, LexinFintech Holdings was featured in research on promising penny stocks, highlighting its strong financial health rating and position within China's consumer finance sector. An interesting angle from this coverage is that LexinFintech is being framed as a lower-priced entry point where fundamentals, rather than speculation, are the primary focus for investors. Against this backdrop of attention on LexinFintech’s financial strength, we’ll examine how this recognition may influence...

Updated guidance puts Xeris Biopharma Holdings (XERS) on investors’ radar Xeris Biopharma Holdings (XERS) lifted its full-year 2025 revenue outlook, now guiding to approximately US$292 million, above the prior US$285 million to US$290 million range. This is a shift that directly affects how investors may view the stock. See our latest analysis for Xeris Biopharma Holdings. The updated revenue outlook arrives after a mixed price run, with a 1-day share price return of 1.48% and a 90-day share...

In January 2026, Polestar Automotive Holding UK PLC reported fourth-quarter 2025 retail sales of 15,608 cars and full-year sales of 60,119, both higher than the prior year. This step-up in retail volumes suggests that Polestar is managing to increase customer deliveries even as competition in the global EV market intensifies. We will now examine how this acceleration in full-year retail sales intersects with concerns about cash burn, competition, and Polestar’s longer-term investment...

In December, Immunome, Inc. reported positive topline results from its Phase 3 RINGSIDE trial, showing Varegacestat improved progression-free survival versus placebo and plans to seek FDA approval in the second quarter of 2026. The data, including a marked reduction in the risk of death or disease progression and a high rate of tumor shrinkage, positions Varegacestat as a potentially important addition to Immunome’s oncology pipeline. Next, we’ll examine how Varegacestat’s strong Phase 3...

IDEAYA Biosciences (IDYA) is back in focus after a cluster of upbeat analyst reports highlighted its precision oncology pipeline and its partnerships with GlaxoSmithKline, Pfizer, and Gilead, drawing fresh attention to the stock. See our latest analysis for IDEAYA Biosciences. After a strong run that leaves the 1 year total shareholder return at 61.59% and the 3 year total shareholder return just over double, recent 7 day and 1 day share price weakness sits against a 90 day share price return...

Asthma data and 2026 pipeline milestones come into focus Apogee Therapeutics (APGE) attracted fresh attention after reporting positive interim Phase 1b data for zumilokibart in mild to moderate asthma, alongside outlining key 2026 milestones across atopic dermatitis and other inflammatory indications. See our latest analysis for Apogee Therapeutics. Against this backdrop, Apogee’s recent asthma update and 2026 pipeline timeline arrive after a strong 90 day share price return of 41.85% and a 1...

In January 2026, Delek US Holdings released a new investor presentation outlining its Enterprise Optimization Plan, expected cash flow enhancements, and capital allocation priorities, alongside benefits from recent EPA small refinery exemption relief that is projected to unlock US$400 million in cash and add US$200 million in annual cash flow. The company is also planning a major turnaround at its Big Spring refinery in early 2026 to improve reliability, optimize its crude slate, and enhance...

If you are wondering whether Organon’s current share price reflects its underlying worth, you are not alone. This article focuses on how its market price compares with its estimated value. Organon’s stock last closed at US$8.76, with recent returns of 8.8% over 7 days, 28.3% over 30 days and 21.0% year to date, while the 1 year and 3 year returns stand at 42.9% and 67.6% declines. These moves come against a backdrop of ongoing attention on Organon’s role in the pharmaceuticals and biotech...

In November 2025, Visby Medical announced that Quest Diagnostics’ consumer platform, questhealth.com, added the FDA-authorized at-home Visby Women’s Sexual Health Test for rapid STI detection, expanding national access to 30-minute, at-home PCR testing for chlamydia, gonorrhea, and trichomoniasis. This move highlights Quest’s push into consumer-initiated women’s health testing, addressing significant gaps in timely STI diagnosis and treatment that can affect fertility. Next, we’ll examine...